Clinical Trial Ethics: When Scientists from Europe and China Join Forces . . .

Pfizer Drops Two Late-Stage Candidates, Citing Little Market Potential

Report: Industry Exhibits “Bias, Spin and Misreporting” of Trial Results

"Heparin Was an Industry Wake-Up Call": A Star Turn by CDER's Janet Woodcock

What Does Lilly and Covance R&D Deal Mean for Industry?

Keeping Track of Pharma Clinical Development Software Providers

Microsoft Discusses SharePoint and Clinical Trials at DIA

GSK and Spitzer: Schadenfreude?

Trasylol Recall May Have Come a Bit Late: 20,000 Patients Too Late, a Researcher Tells 60 Minutes